戈舍瑞林对绝经前乳腺癌患者卵巢功能保护的meta分析

doi:10.3760/cma.j.issn.1007-1245.2024.05.004

摘要/Abstract

摘要：

目的　通过meta分析方法系统评价戈舍瑞林对绝经前乳腺癌患者卵巢功能保护的能力。方法　检索中国知网、万方数据库、维普数据库、PubMed、Web of Science、Scopus及Cochrane Library，提取从建库至2023年10月戈舍瑞林治疗绝经前乳腺癌的对照试验。由2名研究者根据纳入与排除标准独立筛选文献、提取数据，并采用Cochrane协作网风险偏倚评价工具对纳入研究质量进行评价，运用RevMan 5.3软件进行数据分析。结果　共纳入28项研究，共8 782例研究对象，其中试验组4 372例，对照组4 410例。meta分析结果显示：试验组总有效率高于对照组（OR=2.87，95%CI 1.94～4.26，P<0.000 01）；试验组基础卵泡刺激素（bFSH）水平低于对照组（MD=-3.81，95%CI -4.35～-3.27，P<0.000 01）；试验组窦状卵泡数（bAFC）水平高于对照组（MD=3.27，95%CI 2.83～3.72，P<0.000 01）；两组雌二醇（E2）水平比较，差异无统计学意义（SMD=0.85，95%CI -0.69～2.40，P=0.28）；试验组促黄体生成素（LH）高于对照组（MD=8.75，95%CI 7.84～9.67，P<0.000 01）；试验组卵巢早衰（POI）低于对照组（OR=0.24，95%CI 0.08～0.73，P=0.01）；试验组月经复潮率高于对照组（OR=3.09，95%CI 1.01～9.46，P=0.05）；试验组无病生存期（DFS）高于对照组（OR=1.91，95%CI 1.28～2.85，P=0.002）；试验组总生存期（OS）高于对照组（OR=1.35，95%CI 1.14～1.59，P=0.000 4）；试验组无进展生存时间（PFS）高于对照组（MD=30.15，95%CI 29.47～30.83，P<0.000 01）；试验组不良反应发生率低于对照组（OR=0.48，95%CI 0.25～0.90，P=0.02）。结论　戈舍瑞林治疗绝经前乳腺癌患者能有效保护其卵巢功能，提高患者生存时间，同时具有较好的安全性。

关键词:

戈舍瑞林, 绝经前乳腺癌, 卵巢功能, meta分析

Abstract:

Objective　To evaluate the ability of goserelin in the protection of the ovarian function in premenopausal patients with breast cancer by meta-analysis. Methods　The China National Knowledge Infrastructure, Wanfang Database, VIP Database, PubMed, Web of Science, Scopus, and Cochrane Library were searched for the controlled trials of goserelin for premenopausal patients with breast cancer from their establishment to October 2023. Two investigators independently screened the literatures according to the inclusion and exclusion criteria, extracted the data, and evaluated the quality of the included studies using the Cochrane Collaboration risk of bias assessment tool. The data were analyzed using the RevMan 5.3 software. Results　Twenty-eight studies and 8 782 patients were included, including 4 372 in the test group and 4 410 in the control group. The meta-analysis results showed that the total effective rate of the test group was higher than that of the control group (OR=2.87, 95%CI 1.94-4.26, P<0.000 01); the basal follicle-stimulating hormone (bFSH) level of the test group was lower than that of the control group (MD=-3.81, 95%CI -4.35 to -3.27, P<0.000 01); the basal antral follicle counting (bAFC) of the test group was higher than that of the control group (MD=3.27, 95%CI 2.83-3.72, P<0.000 01); the estradiol (E2) level in the test group was not significantly different from that in the control group (SMD=0.85, 95%CI -0.69 to -2.40, P=0.28); the luteinizing hormone (LH) in the test group was higher than that in the control group (MD=8.75, 95%CI 7.84-9.67, P<0.000 01); the premature ovarian failure (POI) in the test group was lower than that in the control group (OR=0.24, 95%CI 0.08-0.73, P=0.01); the menstrual recurrence rate in the test group was higher than that in the control group (OR=3.09, 95%CI 1.01-9.46, P=0.05); the disease-free survival (DFS) in the test group was higher than that in the control group (OR=1.91, 95%CI 1.28-2.85, P=0.002); the overall survival (OS) in the test group was higher than that in the control group (OR=1.35, 95%CI 1.14-1.59, P=0.000 4); the progression-free-survival (PFS) in the test group was higher than that in the control group (MD=30.15, 95%CI 29.47-30.83, P<0.000 01); the incidence of adverse reactions in the test group was lower than that in the control group (OR=0.48, 95%CI 0.25-0.90, P=0.02). Conclusion　Goserelin for premenopausal patients with breast cancer effectively protects their ovarian function and improves their survival time, and is safe.

Key words:

Goserelin, Premenopausal breast cancer, Ovarian function, Meta-analysis

郝慧慧李真真丁传华韩秀媛郭锡春.

戈舍瑞林对绝经前乳腺癌患者卵巢功能保护的meta分析 [J]. 国际医药卫生导报, 2024, 30(5): 721-731.

Hao Huihui, Li Zhenzhen, Ding Chuanhua, Han Xiuyuan, Guo Xichun.

Meta-analysis on goserelin in protection of ovarian function in premenopausal patients with breast cancer [J]. International Medicine and Health Guidance News, 2024, 30(5): 721-731.

参考文献

[1] Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of breast cancer in young women[J]. J Thorac Dis, 2013, 5 Suppl 1:S2-S8. DOI: 10.3978/j.issn.2072-1439.2013.05.24.
[2] Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer[J]. Eur J Cancer, 2012,48(18):3355-3377. DOI: 10.1016/j.ejca.2012.10.004.
[3] Chen HL, Zhou MQ, Tian W, et al. Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database[J]. PLoS One, 2016,11(10):e0165409. DOI: 10.1371/journal.pone.0165409.
[4] Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function[J]. Cancer, 2007,110(10):2222-2229. DOI: 10.1002/cncr.23071.
[5] Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary?[J]. Hum Reprod Update, 2012,18(5):525-535. DOI: 10.1093/humupd/dms022.
[6] Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients[J]. J Clin Oncol, 2006,24(18):2917-2931. DOI: 10.1200/JCO.2006.06.5888.
[7] Letourneau JM, Ebbel EE, Katz PP, et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer[J]. Cancer, 2012,118(7):1933-1939. DOI: 10.1002/cncr.26403.
[8] Kil WJ, Ahn SD, Shin SS, et al. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients[J]. Breast Cancer Res Treat, 2006,96(3):245-250. DOI: 10.1007/s10549-005-9059-x.
[9] Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update[J]. J Clin Oncol, 2018,36(19):1994-2001. DOI: 10.1200/JCO.2018.78.1914.
[10] Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4)[J]. Ann Oncol, 2020,31(6):674-696. DOI: 10.1016/j.annonc.2020.03.284.
[11] Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion[J]. Fertil Steril, 2019,112(6):1022-1033. DOI: 10.1016/j.fertnstert.2019.09.013.
[12] Moore HCF, Unger JM, Phillips KA, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230[J]. J Natl Cancer Inst, 2019,111(2):210-213. DOI: 10.1093/jnci/djy185.
[13] Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women[J]. Cochrane Database Syst Rev, 2019,3(3):CD008018. DOI: 10.1002/14651858.CD008018.pub2.
[14] Kim SE, Kim WJ, Choi D, et al. Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer[J]. Breast Cancer Res Treat, 2023,198(2):231-237. DOI: 10.1007/s10549-023-06877-4.
[15] Abdel-Razeq H. Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer[J]. Cancer Manag Res, 2019,11:4273-4282. DOI: 10.2147/CMAR.S204069.
[16] Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2012,30(5):533-538. DOI: 10.1200/JCO.2011.34.6890.
[17] Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial[J]. Obstet Gynecol, 2013,121(1):78-86. DOI: 10.1097/aog.0b013e31827374e2.
[18] Zong X, Yu Y, Yang H, et al. Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial[J]. JAMA Oncol, 2022,8(2):252-258. DOI: 10.1001/jamaoncol.2021.6214.
[19] Zhang Y, Ji Y, Li J, et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival[J]. Breast Cancer Res Treat, 2018,168(3):679-686. DOI: 10.1007/s10549-018-4660-y.
[20] Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial[J]. Ann Oncol, 2017,28(8):1811-1816. DOI: 10.1093/annonc/mdx184.
[21] Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015,372(10):923-932. DOI: 10.1056/NEJMoa1413204.
[22] Karlsson P, Sun Z, Braun D, et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer[J]. Ann Oncol, 2011,22(10):2216-2226. DOI: 10.1093/annonc/mdq735.
[23] Kaufmann M, Graf E, Jonat W, et al. A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93[J]. Eur J Cancer, 2007,43(16):2351-2358. DOI: 10.1016/j.ejca.2007.08.012.
[24] von Minckwitz G, Graf E, Geberth M, et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93) [J]. Eur J Cancer, 2006,42(12):1780-1788. DOI: 10.1016/j.ejca.2006.04.006.
[25] Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study[J]. Eur J Cancer, 2006,42(7):895-904. DOI: 10.1016/j.ejca.2005.12.013.
[26] Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer[J]. Eur J Cancer, 2003,39(12):1711-1717. DOI: 10.1016/s0959-8049(03)00392-7.
[27] 冷婕,张菠,万霞.女性年轻乳腺癌患者化疗期间卵巢功能的保护[J/CD].中文科技期刊数据库(文摘版)医药卫生,2022(11):0204-0206
[28] 周兆栋.戈舍瑞林治疗年轻三阴性乳腺癌的临床疗效及用药依从性[J].临床合理用药杂志,2022,15(7):79-82.DOI:10.15887/j.cnki.13-1389/r.2022.07.024.
[29] 彭厚坤.戈舍瑞林对绝经前乳腺癌患者辅助化疗期间卵巢功能的保护作用[J].医药前沿,2021,11(24):70-71.
[30] 周仁基,刘晓慧,谭小强.43例高复发风险绝经前乳腺癌患者采用戈舍瑞林联合内分泌治疗的临床研究[J].上海医药,2021,42(15):11-12,89.DOI:10.3969/j.issn.1006-1533. 2021.15.005.
[31] 董小齐.绝经期乳腺癌患者化疗期间采用戈舍瑞林治疗对其卵巢功能的影响[J].数理医药学杂志,2020,33(7):1040-1041.DOI:10.3969/j.issn.1004-4337.2020.07.042.
[32] 聂宝华,曹永丽.戈舍瑞林对绝经前乳腺癌患者基础卵泡刺激素和窦卵泡计数的影响[J].河南医学研究,2020,29(22):4129-4130.DOI:10.3969/j.issn.1004-437X.2020.22.040.
[33] 史纯璞.戈舍瑞林联合内分泌药物治疗绝经前乳腺癌的临床效果分析[J/CD].临床医药文献电子杂志,2020,7(46):145-146.DOI:10.16281/j.cnki.jocml.2020.46.101.
[34] 王沛,田跃军,祁学锋.戈舍瑞林在HR阴性绝经前年轻乳腺癌辅助化疗患者中的应用观察[J].首都食品与医药,2020,27(22):79.DOI:10.3969/j.issn.1005-8257.2020.22.051.
[35] 李志英.绝经前激素受体(HR)阳性的乳腺癌患者使用戈舍瑞林联合AI或者TAM对比TAM的临床效果观察[J].名医,2019(2):99.
[36] 张珂,姚宝国,苏莉,等.促性腺激素释放激素激动剂对激素受体阴性年轻乳腺癌辅助化疗患者卵巢功能的影响及抗苗勒氏管激素检测的价值[J].肿瘤基础与临床,2019,32(6):514-518.DOI:10.3969/j.issn.1673-5412.2019.06.014.
[37] 白文辉.卵巢功能去势在绝经前转移性乳腺癌患者中的应用[J].实用医学杂志,2018,34(23):3952-3956.DOI:10.3969/j.issn.1006-5725.2018.23.026.
[38] 韩媛媛.托瑞米芬联合戈舍瑞林治疗受体阳性绝经前乳腺癌的疗效评估[J].中国医药科学,2018,8(23):60-63.DOI:10.3969/j.issn.2095-0616.2018.23.017.
[39] 全成海,王军.戈舍瑞林在绝经前乳腺癌患者辅助化疗期间卵巢功能的保护作用[J].世界最新医学信息文摘,2018,18(81):112.DOI:10.19613/j.cnki.1671-3141.2018.81.083.
[40] 方丽兰,余更生,李晓平,等.戈舍瑞林对绝经前乳腺癌患者卵巢功能的保护作用[J].实用医学杂志,2017,33(14):2361-2364.DOI:10.3969/j.issn.1006-5725.2017.14.029.
[41] 钱跃军,吕晶,李明闯.戈舍瑞林在绝经前乳腺癌患者辅助化疗中的卵巢功能保护作用[J].广东医学,2017,38(z2):131-133.DOI:10.3969/j.issn.1001-9448.2017.z2.054.
[42] 王亚丽,陈龙舟,李青国,等.抗苗勒管激素用于评价戈舍瑞林对年轻乳腺癌患者卵巢功能抑制作用的前瞻性临床研究[J].现代肿瘤医学,2017,25(22):3596-3599.DOI:10.3969/j.issn.1672-4992.2017.22.012.
[43] 王玲,董桂芝,杜朝晖,等.药物性卵巢去势在绝经前转移性乳腺癌患者中的应用[J].实用药物与临床,2015,(1):9-12.DOI:10.14053/j.cnki.ppcr.201501003.
[44] 鲁静,刘振杰.戈舍瑞林联合内分泌药物治疗绝经前乳腺癌的疗效观察[J].临床合理用药杂志,2013,6(6):58-58.DOI:10.3969/j.issn.1674-3296.2013.06.042.
[45] 贾国丛,赵晓燕,任胜楠.戈舍瑞林对绝经前乳腺癌患者化疗期间卵巢功能的保护[J].中国普通外科杂志,2011,20(11):1188-1191.
[46] Brancati S, Gozzo L, Longo L, et al. Fertility Preservation in female pediatric patients with cancer: a clinical and regulatory issue[J]. Front Oncol, 2021,11:641450. DOI: 10.3389/fonc.2021.641450.
[47] Xie Y, Duan H, Wang D, et al. Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: a prospective study[J]. Front Oncol, 2022,12:986208. DOI: 10.3389/fonc. 2022.986208.
[48] Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016,2(1):65-73. DOI: 10.1001/jamaoncol.2015.3251.
[49] Choi MC, Chung YS, Lee JW, et al. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R) [J]. Eur J Cancer, 2020,133:56-65. DOI: 10.1016/j.ejca.2020.03.030.
[50] Coccia PF, Pappo AS, Beaupin L, et al. Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018,16(1):66-97. DOI: 10.6004/jnccn.2018.0001.